HELP

If you would like to receive a free information packet** or have questions about mesothelioma, call us at:

Toll-Free 1-877-FOR MESO (367-6376)

**Packet includes information on specialists, treatments, clinical trials,
cancer links, and how to access legal and financial resources. You will
be contacted by a Mesothelioma Web co-ordinator who will be available
to discuss questions you might have.

Alfacell shares rose $1.71, or 52.1 percent, to a new 52-week high of
$4.99 in morning trading on the Nasdaq.

The clinical trial seeks to test Onconase for the treatment
of unresectable malignant mesothelioma, a rare form of
cancer linked to asbestos exposure that occurs in the sac lining of the
chest, the abdomen, or the lining of the heart that cannot be surgically
removed. The company expects to enroll 316 patients before the end of
the first quarter, ahead of schedule.

The company said it plans to try to parlay its fast track designation
from the Food and Drug Administration into an expedited review of its
marketing application.

A fast track designation allows a company to submit data to the FDA as
it becomes available, and receive feedback, rather than having to wait
until the end of the trial and submit it all at once. An expedited review
is granted by the agency if the company can show a pressing public health
need for a given treatment.